INSIGNIA

INSIGNIA is a US-based entity operating under the domain insigniafutures.com. According to our records, the broker was founded on March 15, 2019, and is registered at 1821 Walden Office Square – Suite 400, Schaumburg, IL 60173, USA. The firm maintains a Facebook presence but has not been assigned any regulatory oversight from recognized financial authorities.

Our analysis indicates that INSIGNIA presents itself as a commodity futures broker, though we have not been able to verify its operational history or legal status. The absence of regulatory registration is a significant factor for traders to consider, as it means the broker is not subject to the oversight or investor protection schemes typical of regulated entities.

INSIGNIA's regulatory status is a key point of concern. Our records show no active licences from any major financial regulator, including the US Commodity Futures Trading Commission (CFTC) or the National Futures Association (NFA), despite claims on its website to the contrary. This discrepancy between the broker's public statements and our verified data underscores the need for extreme caution.

Without independent verification of regulatory compliance, traders cannot rely on standard safeguards such as segregated client funds, dispute resolution mechanisms, or compensation schemes. The lack of regulatory oversight also means that the broker's operations and financial stability are not subject to routine scrutiny.

Publicly available information about INSIGNIA is limited. The broker's official website provides details about its trading services, platforms, and account types, but our independent research could not confirm the accuracy of these claims. The address provided in our records points to a business park in Schaumburg, Illinois, but we have not verified the nature of the physical presence.

Given the low web confidence resulting from mismatched founding dates and regulatory claims, we advise traders to seek additional sources of information and to approach this broker with heightened scrutiny. The scarcity of independent reviews and the absence of regulatory oversight create an environment of elevated risk.